METTL21C

Across TCGA pan-cancer cohorts, METTL21C RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated METTL21C data layer compared with 2 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher METTL21C RNA is associated with worse overall survival. In most high-consensus cancer types, elevated METTL21C expression acts as an unfavorable survival marker, although some lineages such as LGG and LUAD show a favorable association.

OV, HNSC, and UVM are the cancer types where METTL21C RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.615	0.759	<.001	78	view →
HNSC	DFS	Tertile	III,IV	0.569	0.708	.011	48	view →
UVM	DFS	Median	III,IV	0.328	0.707	.001	46	view →
ACC	OS	Tertile	All	0.341	0.665	.008	45	view →
THCA	OS	Quartile	IV	0.502	0.899	.002	43	view →
ESCA	OS	Tertile	IV	0.095	0.512	.008	36	view →
READ	DFS	Tertile	IV	0.179	0.695	<.001	24	view →
STAD	OS	Quartile	All	0.290	0.444	.019	21	view →
KIRP	DFS	Quartile	II,III,IV	0.194	0.690	.032	15	view →
LUSC	DFS	Median	II,III,IV	0.244	0.439	.006	12	view →
KIRC	OS	Quartile	All	0.534	0.655	.014	11	view →
LGG	OS	Median	All	0.925	0.863	.005	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

METTL21C–OV (OS)

Open the OV breakdown →